Evolus (EOLS) Change in Account Payables (2017 - 2026)
Evolus (EOLS) posted Change in Account Payables of -$7.6 million for Q1 2026, down 471.9% on a QoQ basis from $2.0 million in Q4 2025, and down 261.14% year-over-year from $4.7 million in Q1 2025.
Evolus (EOLS) Change in Account Payables (2017 - 2026) Analysis & Trends
Evolus' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$7.6 million for Q1 2026.
- Quarterly Change in Account Payables fell 261.14% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 153.0% YoY) and the FY2025 annual result came in at $10.1 million, up 2483.89% from the prior year.
- Change in Account Payables was -$7.6 million for Q1 2026 at Evolus, down from $2.0 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.7 million in Q1 2025 and bottomed at -$7.6 million in Q1 2026.
- A 5-year average of $166823.5 and a median of $909000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 1028.57% — and 2024, when it tumbled 508.13%.
- Evolus' Change in Account Payables stood at -$1.4 million in 2022, then tumbled by 323.8% to -$5.8 million in 2023, then soared by 50.24% to -$2.9 million in 2024, then soared by 170.82% to $2.0 million in 2025, then plunged by 471.9% to -$7.6 million in 2026.
- Business Quant data shows EOLS's Change in Account Payables at -$7.6 million in Q1 2026, $2.0 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -7.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.61 Mn |
| Mar 31, 2026 | -7.61 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | -777,000.00 |
| Jun 30, 2025 | -777,000.00 |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | 909,000.00 |
| Mar 31, 2024 | 909,000.00 |
| Dec 31, 2023 | -5.81 Mn |
| Dec 31, 2023 | -5.81 Mn |